DIRECTSENS GMBH

Their core work

DirectSens GmbH is an Austrian biosensor company specializing in enzyme-based electrochemical sensors, with a particular focus on glucose monitoring for medical applications. Their core technical work involves designing enzymes that overcome the major limitations of implantable biosensors — specifically the foreign body response and mass-transfer variability that cause sensor drift over time. They contribute sensor design and bioelectrochemistry expertise to research consortia, bridging the gap between fundamental enzyme engineering and practical wearable or implantable medical devices. Their work spans both continuous wear patches for consumer health monitoring and long-term implantable sensors for chronic disease management.

What they specialise in

How they've shifted over time

Both of DirectSens's H2020 projects started in the same year (2019), so a strict chronological evolution is not possible to establish from this data alone. However, the keyword split reveals two complementary but distinct technical directions: ELSAH brought them into system-level integration (smart patches, wireless monitoring, consumer well-being), while ImplantSens pushed toward fundamental bioscience challenges (foreign body response, enzyme design, long-term implant stability). If there is a trajectory, it runs from wearable/surface-level monitoring toward deeper implantable biosensing, which is technically more demanding and commercially more specialized. This suggests a company moving toward higher-barrier, higher-value medical device territory.

DirectSens appears to be deepening its focus on the hardest unsolved problems in continuous glucose monitoring — long-term implant stability and foreign body response — which positions them for medtech R&D partnerships rather than consumer electronics.

How they like to work

DirectSens participates exclusively as a consortium partner across both projects and has never served as project coordinator, suggesting they operate as a specialist contributor rather than a project driver. With 26 unique partners across 7 countries from just 2 projects, they engage in relatively large, multi-partner consortia typical of RIA and MSCA-ITN projects. This profile indicates they bring a defined technical capability — biosensor chemistry and enzyme design — that consortium leaders actively seek out rather than a broad platform that anchors a project.

DirectSens has worked with 26 unique partners across 7 countries, a notably wide network for a company with only 2 projects, reflecting the large consortium sizes typical of RIA and MSCA training networks. Their geographic reach spans at least 7 European countries, consistent with standard pan-European H2020 consortia.

What sets them apart

DirectSens occupies a rare niche as a private SME with deep enzyme engineering expertise applied specifically to electrochemical biosensors — a space usually dominated by university labs. Their focus on mass-transfer independence and switchable enzymes addresses the primary reason continuous glucose monitors fail over time, which is an unsolved commercial problem worth hundreds of millions in the diabetes management market. For a consortium needing a biosensor technology partner that sits between academic chemistry and commercial device integration, DirectSens offers industrial-grade focus with research-depth expertise.

Highlights from their portfolio

• ImplantSens
  Highest-funded project (EUR 395,938) tackling the fundamental biological and chemical barriers to long-term implantable glucose sensors — a problem that has blocked the medtech industry for decades.
• ELSAH
  Places DirectSens inside a full-stack digital health system (wireless, wearable, self-testing), demonstrating their ability to contribute sensor chemistry within large integrated device consortia.